Slide 1: Technology Solutions that Inform and Empower the Healthcare Community
Technology Solutions that Inform and Empower the Healthcare Community Corporate Presentation March 2026 The content of this presentat ion is proprietary and confidential information of OptimizeRx. It is not intended to be dis tributed to any third party without the written cons ent of OptimizeRx. Al
Slide 2: Important Cautions Regarding Forward Looking Statements
Important Cautions Regarding Forward Looking Statements • This presentation has been prepared by OptimizeRx Corporation (“we,” “us,” “our,” “OptimizeRx” Instead, they are based only on our current beliefs, expectations and assumptions regarding the or the “Company”) and is made for informational p
Slide 3: At-a-Glance
At-a-Glance Leading technology provider for helping patients start and stay on therapy Corporate Profile Stock Information OptimizeRx enables engagement between life sciences Stock Price (as of 3/12/26) $5.93 organizations, physicians and patients Shares Outstanding OptimizeRx connects pharma with p
Slide 4: Tackling Some Of Pharma's Toughest Commercial Challenges
Tackling Some Of Pharma’s Toughest Commercial Challenges BRAND VISIBILITY SHIFT TO SPECIA LTY MEDICATIONS Crowded market 13% see strong HCP-DTC marketing alignment, Limited Face to Face time and only 16% think patients are well informed(2) DAILY EHR USE CAN BE ALL-CONSUMING AFFORDABILITY HCPs use EH
Slide 5: Our Mission / DAAP Helps Deliver on Our Mission
Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community with a technology platform that helps people start and stay on life-impacting therapies. DAAP Helps Deliver on Our Mission Our Dynamic Audience Activation Platform (DAAP) delivers predictive and privacy-sa
Slide 6: Growth Leaders | Growth Drivers
Growth Leaders | Growth Drivers EXPERIENCE EXPERIENCE 20+ Operations, Management, Sales, and Growing 20+ Senior Financial & Operational Roles Partner Networks S TE V E SI L VE S TR O E D ST E LM AK H Chief Executive Officer Chief Financial & Strategic Officer EXPERIENCE EXPERIENCE EXPERIENCE Senior
Slide 7: Technology that Connects the Healthcare Community
Technology that Connects the Healthcare Community PHARMA High ROI Connect to key customers Support brand market performance Reach into Top 20 Pharma ~400 Brands +2 MM +240 MM HCPs Patients PATIENTS Relevant treatment information +300 EHRs Productive care discussions HEALTHCARE PROFESSIONALS Navigati
Slide 8: AI-Enabled Platform Achieves Effective and Efficient Marketing Execution
AI-Enabled Platform Achieves Effective and Efficient Marketing Execution DIG ITAL AUDIO / O OH* DIRECT M AIL / EMAIL* CTV / ATV / OTT* DAAP deals typically range DIG ITA L DI SPLAY* between ~$0.5M - $1.5 million SO CIA L* Dynamic Weekly DIG ITA L POC NPI Lists FIELD FORCE 8 The content of this prese
Slide 9: Driving Brand Demand Through AI-Driven Platform
Driving Brand Demand Through AI-Driven Platform CL IE NT G OA L A brand sought to increase awareness among physicians treating newly diagnosed and relapsing rare disease patients. CL IE NT C HA LLEN GE S • Creating awareness among physicians likely to see patient population earlier in the patient jo
Slide 10: Increasing Brand Touchpoints and Script Lift with Platform
Increasing Brand Touchpoints and Script Lift with Platform CL IE NT G OA L Increase the number of oncology brand touchpoints by capitalizing on HCP social media presence. CL IE NT C HA LLEN GE S • Multi-indication therapy needed to keep suitability for numerous diseases top-of-mind. • Oncologists hi
Slide 11: Large, Under Penetrated Market With Tailwinds Driven by Increased Pharma Advertising Spend
Large, Under Penetrated Market With Tailwinds Driven by Increased Pharma Advertising Spend on Digital Channels 25.0 U.S. Pharma Digital Ad Spend ($ billions) 21.6 20.2 20.0 19.5 17.0 15.0 15.0 10.0 5.0 0.0 2022 2023 2024 2025 2026 Source: Leventhal, Rajiv. “Pharma Accounts for Nearly 90% of the Broa
Slide 12: Unique Capabilities of the Dynamic Audience Activation Platform (DAAP)
Unique Capabilities of the Dynamic Audience Activation Platform (DAAP) Accessible Market Opportunity for Combined Solution Set (HCP/DTC) ~350 Brands supported Current opportunity with with 45% coverage existing brands represents of the top 200 brands a $2B - $3B opportunity ~10% of brands utilize ~1
Slide 13: Key Performance Indicators
Key Performance Indicators Our footprint in the top 20 pharmaceutical manufacturers positions us well to compete and win our share of the largest category of addressable commercial spend Definition of Key Performance Indicators (KPIs) Trailing Twelve Months December 31, December 31, • Top 20 pharmac
Slide 14: Strong Financial Momentum
Strong Financial Momentum $109-$114 (E) Q4 2025 RESULTS ANNUAL REVENUE GROWTH $109 (millions) $92 $32.2M Revenue $72 $61 $62 Fiscal 2026 guidance calls for $5.0M $43 revenue between $109M and $114M GAAP Net with an adjusted Income EBITDA between $21M and $25M. $25 $21 $12.0M $5 $7 $7 $8 $12 Adjusted
Slide 15: Key Takeaways
Key Takeaways HIGHLY SCALABLE PROVE N HEALTHCARE PLATFORM TECHNOLOGY LARGE & EXPANDING SUS TAINABLE MARKET OP PORTUNITY COMPETITIV E ADVANTAGE 15 The content of this presentat ion is proprietary and confidential information of OptimizeRx. It is not intended to be dis tributed to any third party with
Slide 16: Reconciliation of GAAP to NON-GAAP Financial Measures
Reconciliation of GAAP to NON-GAAP FINANCIAL MEASURES (in thousands, except share and per share data, unaudited) • This presentation includes certain financial measures not derived in accordance with generally accepted accounting principles (GAAP). These non- GAAP financial measures are measures of